Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader… - Clinical …, 2022 - clinicalmicrobiologyandinfection …
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
Immunocompromised patients have been neglected in COVID-19 trials: a call for action.
M Trøseid, M Hentzien, F Ader… - … and Infection: the …, 2022 - europepmc.org
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
[PDF][PDF] Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader… - Clinical …, 2022 - access.archive-ouverte.unige.ch
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
[PDF][PDF] Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader, SW Cardoso… - Clinical Microbiology …, 2022 - dipot.ulb.ac.be
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader… - … and infection: the …, 2022 - pubmed.ncbi.nlm.nih.gov
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
Immunocompromised patients have been neglected in COVID-19 trials: a call for action Clin …
Immunocompromised patients have been neglected in COVID-19 trials: a call for action Clin …
[HTML][HTML] Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader… - Clinical Microbiology …, 2022 - ncbi.nlm.nih.gov
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader, SW Cardoso… - 2022 - arca.fiocruz.br
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
[引用][C] Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trųseid, M Hentzien, F Ader… - Clinical microbiology …, 2022 - difusion.ulb.ac.be
[引用][C] Immunocompromized patients have been neglected in Covid-19 trials: A call for action
M Troseid, M Hentzien, F Ader, SW Cardoso… - Clinical Microbiology …, 2022 - hal.science
Immunocompromized patients have been neglected in Covid-19 trials: A call for action -
Archive ouverte HAL Accéder directement au contenu Documentation FR Français (FR) …
Archive ouverte HAL Accéder directement au contenu Documentation FR Français (FR) …
Immunocompromised patients have been neglected in COVID-19 trials: a call for action
M Trøseid, M Hentzien, F Ader, SW Cardoso… - 2022 - arca.fiocruz.br
Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …